Abstract
A 47-year-old Caucasian man developed mild diarrhoea associated with more than 10 kg weight loss, severe fatigue and anaemia. Endoscopy demonstrated deposits of AA amyloid within the gastrointestinal tract. He had heavy proteinuria with a serum albumin of 15 g/L consistent with systemic AA amyloidosis. He had no symptoms to suggest an underlying chronic inflammatory condition but had CRP 130 mg/L and SAA 474 mg/L. In an attempt to identify the source of his inflammatory response, he underwent a contrast-enhanced whole-body computed tomography scan, which revealed a necrotising mass lesion in the right kidney consistent with a renal cell carcinoma. It also showed non-mechanical obstruction of the small bowel and, immediately post-imaging, the patient developed intractable vomiting followed by oliguric renal failure requiring haemodialysis. Despite his renal and gut failure, he underwent right radical nephrectomy without further complications. Histology showed complete resection of a clear cell renal cell carcinoma and renal amyloid deposits. Post-surgery, his acute-phase response decreased to normal, consistent with the renal cell carcinoma acting as the inflammatory stimulus. Although he remains dialysis dependent, his gut function improved and he has regained both normal weight and serum albumin. Our case demonstrates partial resolution of AA amyloidosis with removal of the inflammatory source.
References
Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med. 1982;73:426–8. PMID 7124769.
Jaakkola H, Törnroth T, Groop PH, Honkanen E. Renal failure and nephrotic syndrome associated with gastrointestinal stromal tumour (GIST)—a rare cause of AA amyloidosis. Nephrol Dial Transplant. 2001;16:1517–8.
Agha I, Mahoney R, Beardslee M, Liapis H, Cowart RG, Juknevicius I. Systemic amyloidosis associated with pleomorphic sarcoma of the spleen and remission of nephrotic syndrome after removal of the tumor. Am J Kidney Dis. 2002;40:411–41.
Mata M, Lohr T, Lakshminarayanan M, Lo KH, Prabhakar U. Centocor, Inc., Malvern, PA. Serum amyloid A (SAA), C-reactive protein (CRP) and IL-6 as prognostic indicators in renal cell carcinoma and prostate cancer. J Clin Oncol. 2004;22(14S):9711.
Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103(1):101–11. Epub 2010 Jun 8.
Berger L, Sinkoff MW. Systemic manifestations of hypernephroma review of 273 cases. Am J Med. 1957;22:791–6.
Dictor M, Hasserius R. Systemic amyloidosis and non-hematologic malignancy in a large autopsy series. Acta Pathol Microbiol Scand A. 1981;89(6):411–6.
Lavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med. 1978;418:1020–31.
Westermark GT, Sletten K, Grubb A, Westermark P. AA-amyloidosis. Tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am J Pathol. 1990;137(2):377–83. PMID 2386201.
Azzopardi JG, Lehner T. Systemic amyloidosis and malignant disease. J Clin Pathol. 1966;19(6):539–48.
Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607–10.
Rossi J-F, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62. doi:10.1038/sj.bjc.6605872.
Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–56.
Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003;21:343.
Falck HM, Maury CP, Teppo AM, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed). 1983;286:1391.
Lovat LB, Madhoo S, Pepys MB, Hawkins PN. Long-term survival in systemic amyloid A amyloidosis complicating Crohn’s disease. Gastroenterology. 1997;112:1362–5.
Waldenström H. On the formation and disappearance of amyloid in man. Acta Chir Scand. 1928;63:479–530.
Shimojima Y, Takei Y, Tazawa K, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman’s disease. Amyloid. 2006;13:184–6.
Ortiz-Santamaría V, Olivé A, Valls-Roc M, Tena X. Treatment of AA amyloid with chlorambucil. Rheumatology (Oxford). 2002;41:833.
Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22:371–5.
Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford). 2003;42:362–6.
Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20:2051–7.
Uda H, Yokota A, Kobayashi K, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006;33(8):1482–7. PMID 16881107.
Conflict of interest
We do not declare any conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Babu, A., Lachmann, H., Pickett, T. et al. Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep 3, 68–74 (2014). https://doi.org/10.1007/s13730-013-0088-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-013-0088-8